購物車 
-
JNJ-678
- names：
JNJ-678
- CAS號：
1383450-81-4
MDL Number： MFCD30489307 - MF(分子式)： C21H20ClF3N4O3S MW(分子量)： 500.92
- EINECS:No data available Reaxys Number:No data available
- Pubchem ID:118892432 Brand:BIOFOUNT
JNJ-678 (1383450-81-4,JNJ-53718678) 是新型融合蛋白 (fusion protein) 抑制劑，有潛力用于呼吸道合胞病毒 (RSV)的研究。
| 貨品編碼 | 規格 | 純度 | 價格 (￥) | 現價(￥) | 特價(￥) | 庫存描述 | 數量 | 總計 (￥) |
|---|---|---|---|---|---|---|---|---|
| YZM000872-10mg | 10mg | 98% | ￥ 7594.00 | ￥ 7594.00 | 2-3天 | ￥ 0.00 | ||
| YZM000872-5mg | 5mg | 98% | ￥ 4488.00 | ￥ 4488.00 | 2-3天 | ￥ 0.00 |
| 中文別名 | JNJ-678(1383450-81-4);JNJ-53718678;Rilematovir |
| 英文別名 | JNJ-678(1383450-81-4) |
| CAS號 | 1383450-81-4 |
| Inchi | InChI=1S/C21H20ClF3N4O3S/c1-33(31,32)8-2-7-27-16(10-14-9-15(22)3-4-17(14)27)12-28-19-11-26-6-5-18(19)29(20(28)30)13-21(23,24)25/h3-6,9-11H,2,7-8,12-13H2,1H3 |
| InchiKey | GTQTUABHRCWVLL-UHFFFAOYSA-N |
| 分子式 Formula | C21H20ClF3N4O3S |
| 分子量 Molecular Weight | 500.92 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度65 mg/mL(129.76 mM;Need ultrasonic)H2O< 0.1 mg/mL(insoluble) |
| 性狀 | 白色至灰白色固體粉末 |
| 儲藏條件 Storage conditions | -20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月 |
JNJ-678 (1383450-81-4,JNJ-53718678)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染
JNJ-678 (1383450-81-4,JNJ-53718678) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:JNJ-678 (1383450-81-4,JNJ-53718678),NJ-678試劑,NJ-678抑制劑,NJ-678的生產,NJ-678的純度,NJ-678的作用,NJ-678的含量,NJ-678的使用,NJ-678的合成,NJ-678的MSDS,NJ-678的價格,NJ-678的外觀,NJ-678的溶解度
| 產品說明 | JNJ-678 (1383450-81-4,JNJ-53718678) 是新型融合蛋白的抑制劑，臨床試驗中用于治療呼吸道合胞病毒 (RSV) |
| Introduction | JNJ-678 (1383450-81-4,JNJ-53718678) is a novelfusion proteininhibitor in clinical trials for the treatment of respiratory syncytial virus (RSV). |
| Application1 | |
| Application2 | |
| Application3 |
| 警示圖 | |
| 危險性 | warning |
| 危險性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害 |
| 安全防護 | P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理 |
| 備注 | 實驗過程中防止吸入、食入，做好安全防護 |
| Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference PMID 30974127; Antiviral research 2019 07; 167(?):45-67 (Review Article) |
| Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor PMID 31832988; |
| A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scores |
| Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor PMID 28761099; Nature communications 2017 08; 8(1):167 |
| Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference PMID 30974127; Antiviral research 2019 07; 167(?):45-67 (Review Article) |
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor
Abstract:Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly. Intervention with small-molecule antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compounds are approved today. Here we report the structure of JNJ-53718678 bound to respiratory syncytial virus fusion (F) protein in its prefusion conformation, and we show that the potent nanomolar activity of JNJ-53718678, as well as the preliminary structure-activity relationship and the pharmaceutical optimization strategy of the series, are consistent with the binding mode of JNJ-53718678 and other respiratory syncytial virus fusion inhibitors. Oral treatment of neonatal lambs with JNJ-53718678, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible. Together, these data suggest that JNJ-53718678 is a promising candidate for further development as a potential therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.
Abstract:Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly. Intervention with small-molecule antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compounds are approved today. Here we report the structure of JNJ-53718678 bound to respiratory syncytial virus fusion (F) protein in its prefusion conformation, and we show that the potent nanomolar activity of JNJ-53718678, as well as the preliminary structure-activity relationship and the pharmaceutical optimization strategy of the series, are consistent with the binding mode of JNJ-53718678 and other respiratory syncytial virus fusion inhibitors. Oral treatment of neonatal lambs with JNJ-53718678, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible. Together, these data suggest that JNJ-53718678 is a promising candidate for further development as a potential therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.
對不起，暫無產品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關產品
-
< >
- 推薦產品
-
< >
- 最新產品
-
< >
新聞
怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色，是通過細胞爬片是讓玻片浸在細胞培養基內，細胞在玻片上生長，主要用于組織學，免疫組織化學...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
細胞培養耗材技術領先性
細胞培養板行業面臨的核心痛點是：常規TC處理后表面親水角隨時間衰減，影響長期培養穩定性，BIOFOUNT高分...
2026/4/28 15:12:51
細胞培養耗材關鍵性能
細胞培養板的水接觸角作為表面潤濕性的核心指標，直接影響細胞貼壁、增殖、分化及功能表達，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對銅、鐵和其他重金屬?的偏好顯著高于對鈉、鉀等一價陽離子的偏好。它對二價...
2025/11/4 14:22:46
9月開學季——助研新學期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術與國際市場的雙重突破
在實驗室耗材領域，封口膜是保障實驗準確性與穩定性的關鍵產品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領域的國產技術突破和品牌突破，是生物領域中國技術發展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環節，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
